Table 4.
Estimated significant (p < 0.05, one-sided) odds ratio of the risk of cancer incidence vs. virus infection (multivariate regression).
| Comparison | Virus | OR | 95% Cl | p-Value |
|---|---|---|---|---|
| Endometroid endometrial cancer vs. control group | HPV16 | 2.410 | 0.566–10.270 | 0.234 |
| HPV18 | 3.290 | 0.950–11.355 | 0.060 | |
| HCMV | 19.910 | 2.481–159.690 | 0.005 | |
| EBV | 4.780 | 0.514–44.469 | 0.169 | |
| Ovarian cancer (group A) vs. control group | HPV16 | 37.600 | 4.664–303.078 | 0.0007 |
| HPV18 | 5.750 | 1.673–19.762 | 0.0055 | |
| HCMV | 7.903 | 0.881–70.8778 | 0.0647 | |
| EBV | 16.333 | 1.963–135.906 | 0.0098 | |
| Ovarian cancer (group B) vs. control group | HPV16 | 3.620 | 0.651–20.072 | 0.1470 |
| HPV18 | 5.227 | 1.202–22.740 | 0.0275 | |
| HCMV | 16.333 | 1.670–159.760 | 0.0164 | |
| EBV | 3.267 | 0.1930–55.441 | 0.4126 |
HPV16/18, human papillomavirus genotyping 16/18; HMCV, human cytomegalovirus; EBV, Epstein–Barr virus; OR, odds ratio; 95% CL, 95% confidence interval.